NYSE:ZYME Zymeworks (ZYME) Stock Forecast, Price & News $8.23 +0.05 (+0.61%) (As of 05/31/2023 ET) Add Compare Share Share Today's Range$8.06▼$8.3050-Day Range$8.07▼$10.2252-Week Range$4.11▼$10.80Volume850,674 shsAverage Volume635,097 shsMarket Capitalization$528.12 millionP/E Ratio3.18Dividend YieldN/APrice Target$12.44 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Zymeworks MarketRank™ ForecastAnalyst RatingModerate Buy2.56 Rating ScoreUpside/Downside51.2% Upside$12.44 Price TargetShort InterestN/ADividend StrengthN/ASustainabilityN/ANews Sentiment0.40Based on 3 Articles This WeekInsider TradingAcquiring Shares$1.60 M Bought Last QuarterProj. Earnings GrowthGrowingFrom ($2.31) to ($1.22) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.35 out of 5 starsMedical Sector272nd out of 1,006 stocksPharmaceutical Preparations Industry127th out of 492 stocks 3.3 Analyst's Opinion Consensus RatingZymeworks has received a consensus rating of Buy. The company's average rating score is 2.56, and is based on 5 buy ratings, 4 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $12.44, Zymeworks has a forecasted upside of 51.2% from its current price of $8.23.Amount of Analyst CoverageZymeworks has only been the subject of 4 research reports in the past 90 days. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for ZYME. Previous Next 0.0 Dividend Strength Dividend YieldZymeworks does not currently pay a dividend.Dividend GrowthZymeworks does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ZYME. Previous Next 1.9 News and Social Media Coverage News SentimentZymeworks has a news sentiment score of 0.40. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.79 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Zymeworks this week, compared to 3 articles on an average week.Search InterestOnly 17 people have searched for ZYME on MarketBeat in the last 30 days. This is a decrease of -19% compared to the previous 30 days.MarketBeat Follows4 people have added Zymeworks to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Zymeworks insiders have bought 6,764.01% more of their company's stock than they have sold. Specifically, they have bought $1,600,000.00 in company stock and sold $23,310.00 in company stock.Percentage Held by InsidersOnly 1.63% of the stock of Zymeworks is held by insiders.Percentage Held by Institutions88.28% of the stock of Zymeworks is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for Zymeworks are expected to grow in the coming year, from ($2.31) to ($1.22) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Zymeworks is 3.18, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 138.42.Price to Earnings Ratio vs. SectorThe P/E ratio of Zymeworks is 3.18, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 128.11.Price to Book Value per Share RatioZymeworks has a P/B Ratio of 1.54. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Zymeworks (NYSE:ZYME) StockZymeworks, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel, multifunctional biotherapeutics. Its product includes Zanidatamab, which is a novel bispecific antibody that targets two distinct domains of the human epidermal growth factor receptor 2 (HER2). Zanidatamab's unique binding properties result in multiple mechanisms of action that may enable it to address unmet need in patient populations with HER2-expressing cancers. The company was founded on September 8, 2003 and is headquartered in Middletown, DE.Read More Receive ZYME Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Zymeworks and its competitors with MarketBeat's FREE daily newsletter. Email Address ZYME Stock News HeadlinesMay 29, 2023 | markets.businessinsider.comStifel Nicolaus Remains a Buy on Zymeworks (ZYME)May 26, 2023 | americanbankingnews.comBrokerages Set Zymeworks Inc. (NYSE:ZYME) Target Price at $12.44May 31, 2023 | Behind the Markets (Ad)How A.I. Could Make Most 21st Century Diseases EXTINCTOn December 22, 2022, AI discovered a new treatment for multiple myeloma... in just 4 months... On March 19, 2023, AI discovered a new drug for liver cancer... in only 30 days... There's one small-cap at the center of it all. Bill Gates owns 7 million shares... Billionaire hedge-fund manager Steve Cohen owns 1.4 million shares...May 25, 2023 | markets.businessinsider.comZymeworks (ZYME) Gets a Buy from Stifel NicolausMay 21, 2023 | americanbankingnews.comZymeworks (NYSE:ZYME) Trading Up 4.3% After Analyst UpgradeMay 19, 2023 | americanbankingnews.comZymeworks (NYSE:ZYME) PT Raised to $18.00 at CitigroupMay 18, 2023 | msn.comCitigroup Maintains Zymeworks BC (ZYME) Buy RecommendationMay 18, 2023 | marketwatch.comZymeworks President, Chief Operating Officer Neil Klompas to Leave >ZYMEMay 31, 2023 | Legacy Research (Affiliate) (Ad)Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New ForecastHe predicted the 2020 crash a month before it happened… He predicted this year’s collapse back in January… And now, he’s issuing a brand-new warning – along with a unique solution.May 18, 2023 | markets.businessinsider.comWhat 6 Analyst Ratings Have To Say About ZymeworksMay 18, 2023 | americanbankingnews.comZymeworks (NYSE:ZYME) Shares Down 6.9% May 17, 2023 | markets.businessinsider.comStifel Nicolaus Keeps Their Buy Rating on Zymeworks (ZYME)May 11, 2023 | americanbankingnews.comStifel Nicolaus Boosts Zymeworks (NYSE:ZYME) Price Target to $19.00May 11, 2023 | americanbankingnews.comZymeworks (NYSE:ZYME) Shares Gap Up on Analyst UpgradeMay 11, 2023 | finanznachrichten.deZymeworks Inc.: Zymeworks Provides Corporate Update and Reports First Quarter 2023 Financial ResultsMay 11, 2023 | msn.comZymeworks Non-GAAP EPS of -$0.34 beats by $0.20, revenue of $35.58M beats by $16.06MMay 11, 2023 | benzinga.comZymeworks shares are trading higher after the company reported better-than-expected Q1 adjusted EPS and sales results.May 11, 2023 | msn.comZymeworks GAAP EPS of -$0.37 beats by $0.12, revenue of $35.58M beats by $16.06MMay 8, 2023 | seekingalpha.comZymeworks Inc. 2023 Q1 - Results - Earnings Call PresentationMay 8, 2023 | finance.yahoo.comZymeworks Provides Corporate Update and Reports First Quarter 2023 Financial ResultsMay 8, 2023 | markets.businessinsider.comWhat Wall Street expects from Zymeworks's earningsMay 6, 2023 | americanbankingnews.comZymeworks (ZYME) to Release Earnings on MondayMay 1, 2023 | americanbankingnews.comZymeworks Inc. (NYSE:ZYME) Given Average Rating of "Moderate Buy" by AnalystsApril 27, 2023 | seekingalpha.comZymeworks, Jazz in pact over cancer antibody zanidatamabApril 24, 2023 | americanbankingnews.comBrokerages Set Zymeworks Inc. (NYSE:ZYME) Target Price at $12.22April 19, 2023 | americanbankingnews.comComparing Zymeworks (NYSE:ZYME) & PepGen (NASDAQ:PEPG)April 18, 2023 | finance.yahoo.comZymeworks Presents New Data from Multiple Preclinical and Clinical Development Programs at the 2023 American Association for Cancer Research Annual MeetingSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive ZYME Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Zymeworks and its competitors with MarketBeat's FREE daily newsletter. Email Address ZYME Company Calendar Last Earnings5/08/2023Today5/31/2023Next Earnings (Estimated)8/03/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNYSE:ZYME Previous SymbolNASDAQ:ZYME CUSIPN/A CIK1403752 Webwww.zymeworks.com Phone(302) 274-8744Fax604-737-7077Employees455Year FoundedN/APrice Target and Rating Average Stock Price Forecast$12.44 High Stock Price Forecast$19.00 Low Stock Price Forecast$8.00 Forecasted Upside/Downside+51.2%Consensus RatingModerate Buy Rating Score (0-4)2.56 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)$2.59 Trailing P/E Ratio3.18 Forward P/E RatioN/A P/E GrowthN/ANet Income$124.34 million Net Margins38.69% Pretax MarginN/A Return on Equity77.65% Return on Assets46.78% Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$412.48 million Price / Sales1.28 Cash FlowN/A Price / Cash FlowN/A Book Value$5.35 per share Price / Book1.54Miscellaneous Outstanding Shares64,170,000Free Float63,125,000Market Cap$528.12 million OptionableOptionable Beta0.97 Key ExecutivesKen GalbraithChairman & Chief Executive OfficerNeil A. KlompasPresident & Chief Operating OfficerChristopher AstleChief Financial Officer & Senior Vice PresidentMark HollywoodEVP, Head-Technical & Manufacturing OperationsKaycia WildeVice President-Clinical OperationsKey CompetitorsLiquidiaNASDAQ:LQDAPhibro Animal HealthNASDAQ:PAHCPhathom PharmaceuticalsNASDAQ:PHATCalliditas Therapeutics AB (publ)NASDAQ:CALTBicycle TherapeuticsNASDAQ:BCYCView All CompetitorsInsiders & InstitutionsState Street CorpBought 51,032 shares on 5/16/2023Ownership: 0.238%Balyasny Asset Management L.P.Bought 57,078 shares on 5/16/2023Ownership: 0.089%Susquehanna International Group LLPSold 54,500 shares on 5/16/2023Ownership: 0.000%Geode Capital Management LLCBought 31,500 shares on 5/16/2023Ownership: 0.049%BlueCrest Capital Management LtdBought 30,987 shares on 5/16/2023Ownership: 0.048%View All Insider TransactionsView All Institutional Transactions ZYME Stock - Frequently Asked Questions Should I buy or sell Zymeworks stock right now? 9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Zymeworks in the last year. There are currently 4 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ZYME shares. View ZYME analyst ratings or view top-rated stocks. What is Zymeworks' stock price forecast for 2023? 9 Wall Street analysts have issued 12 month price targets for Zymeworks' stock. Their ZYME share price forecasts range from $8.00 to $19.00. On average, they predict the company's share price to reach $12.44 in the next year. This suggests a possible upside of 51.4% from the stock's current price. View analysts price targets for ZYME or view top-rated stocks among Wall Street analysts. How have ZYME shares performed in 2023? Zymeworks' stock was trading at $7.86 at the beginning of the year. Since then, ZYME stock has increased by 4.6% and is now trading at $8.22. View the best growth stocks for 2023 here. When is Zymeworks' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023. View our ZYME earnings forecast. How were Zymeworks' earnings last quarter? Zymeworks Inc. (NYSE:ZYME) announced its quarterly earnings results on Monday, May, 8th. The company reported ($0.37) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.64) by $0.27. The firm earned $35.58 million during the quarter, compared to analysts' expectations of $8.73 million. Zymeworks had a net margin of 38.69% and a trailing twelve-month return on equity of 77.65%. What ETFs hold Zymeworks' stock? ETFs with the largest weight of Zymeworks (NYSE:ZYME) stock in their portfolio include Virtus LifeSci Biotech Clinical Trials ETF (BBC), iShares Biotechnology ETF (IBB), What is Ali Tehrani's approval rating as Zymeworks' CEO? 9 employees have rated Zymeworks Chief Executive Officer Ali Tehrani on Glassdoor.com. Ali Tehrani has an approval rating of 100% among the company's employees. This puts Ali Tehrani in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 86.0% of employees surveyed would recommend working at Zymeworks to a friend. What other stocks do shareholders of Zymeworks own? Based on aggregate information from My MarketBeat watchlists, some companies that other Zymeworks investors own include Advanced Micro Devices (AMD), Gilead Sciences (GILD), Just Energy Group (JE), NVIDIA (NVDA), Just Energy Group (JE), PayPal (PYPL), Alibaba Group (BABA), Cronos Group (CRON), CRISPR Therapeutics (CRSP) and Tesla (TSLA). When did Zymeworks IPO? (ZYME) raised $65 million in an initial public offering on Friday, April 28th 2017. The company issued 4,500,000 shares at a price of $13.00-$16.00 per share. Citigroup, Barclays, Wells Fargo Securities and Canaccord Genuity acted as the underwriters for the IPO and Cormark Securities was co-manager. What is Zymeworks' stock symbol? Zymeworks trades on the New York Stock Exchange (NYSE) under the ticker symbol "ZYME." Who are Zymeworks' major shareholders? Zymeworks' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include EcoR1 Capital LLC (15.73%), Perceptive Advisors LLC (5.26%), Rubric Capital Management LP (4.45%), Credit Suisse AG (3.87%), Farallon Capital Management LLC (3.12%) and BlackRock Inc. (1.17%). Insiders that own company stock include Ali Tehrani, Christopher Astle, Diana Hausman, Ecor1 Capital, Llc, James Priour, Kathryn O'driscoll, Neil A Klompas and Neil Josephson. View institutional ownership trends. How do I buy shares of Zymeworks? Shares of ZYME stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Zymeworks' stock price today? One share of ZYME stock can currently be purchased for approximately $8.22. How much money does Zymeworks make? Zymeworks (NYSE:ZYME) has a market capitalization of $527.48 million and generates $412.48 million in revenue each year. The company earns $124.34 million in net income (profit) each year or $2.59 on an earnings per share basis. How many employees does Zymeworks have? The company employs 455 workers across the globe. How can I contact Zymeworks? Zymeworks' mailing address is 1385 WEST 8TH AVENUE SUITE 540, VANCOUVER A1, V6H 3V9. The official website for the company is www.zymeworks.com. The company can be reached via phone at (302) 274-8744, via email at ir@zymeworks.com, or via fax at 604-737-7077. This page (NYSE:ZYME) was last updated on 5/31/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zymeworks Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.